Hopp til innhold
Close

Get alerts of updates about «Tapering for pregnant women in opioid maintenance treatment (OMT)»

How often would you like to receive alerts from fhi.no? (This affects all your alerts)
Do you also want alerts about:

The email address you register will only be used to send you these alerts. You can cancel and delete your email address at any time by following the link in the alerts you receive.
Read more about the privacy policy for fhi.no

You have subscribed to alerts about:

  • Tapering for pregnant women in opioid maintenance treatment (OMT)

Oops, something went wrong...

... contact nettredaksjon@fhi.no.

... reload the page and try again-

Project

Tapering from buprenorphine or methadone for pregnant women in opioid maintenance treatment (OMT) - project description

Published

Norwegian Institute of Public Health has been commissioned by the Norwegian Directorate of Health to carry out a systematic review of effects of methadone or buprenorphine tapering during pregnancy.


Summary

Norwegian experts disagree in the question of whether women who become pregnant during opioid maintenance treatment (OMT), should have their OMT drug (methadone or buprenorphine) tapered, or whether they should continue maintenance treatment. We will systematically summarise research of effects for mother and child of tapering compared to continued maintenance treatment during pregnancy.

Project number

RL 023

Duration

6 mnd.

Start

04.2018

End

09.2018

Status

Concluded

Principal institution

Project owner/ Project manager

Folkehelseinstituttet

Project manager

Hege Kornør

Participant at FHI

Hilde Helene Holte

Gerd Monika Flodgren

Kjetil Gundro Brurberg

Intern fagfelle: Marte Handal (område for psykisk og fysisk helse, FHI)

External participants

Eksterne fagfeller oppnevnt av Helsedirektoratet: Gabrielle Welle-Strand (Helsedirektoratet), Fatemeh Chalabianloo (Haukeland universitetssjukehus), Yngvar Thorjussen (Borgestadklinikken)